Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia

This single-armed prospective study conducted through the Institute of Hematology & Blood Diseases Hospital in China aims to evaluate the safety and efficacy of human umbilical cord-derived mesenchymal stem cells(hUC-MSCs) to treat refractory immune thrombocytopenia. The study also aims to better understand how hUC-MSCs work mechanistically to treat ITP through observing changes in the immune function with human umbilical cord-derived mesenchymal stem cells(hUC-MSCs) after infusion. Eligibility includes adults between the ages of 18-60 years with a platelet count less than 30K microliters who have had a splenectomy more than 3 months prior to being recruited into the study. The investigators will observe the changes of immune function in refractory ITP patients after hUC-MSCs infusion at 7 time points, including one day before hUC-MSCs infusion, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16weeks and 28 weeks after hUC-MSCs infusion.



back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo